Cargando…
What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
Several treatment options are available for chronic lymphocytic leukemia (CLL) and, for this reason, treatment choice can result challenging after introducing oral targeted agents. This study aims at comparing patients’ and hematologists’ preferences for attributes of CLL treatments. An online cross...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436277/ https://www.ncbi.nlm.nih.gov/pubmed/36081648 http://dx.doi.org/10.1097/HS9.0000000000000771 |
_version_ | 1784781324077236224 |
---|---|
author | Laurenti, Luca Gaidano, Gianluca Mauro, Francesca Romana Molica, Stefano Pasqualetti, Patrizio Scarfò, Lydia Ghia, Paolo |
author_facet | Laurenti, Luca Gaidano, Gianluca Mauro, Francesca Romana Molica, Stefano Pasqualetti, Patrizio Scarfò, Lydia Ghia, Paolo |
author_sort | Laurenti, Luca |
collection | PubMed |
description | Several treatment options are available for chronic lymphocytic leukemia (CLL) and, for this reason, treatment choice can result challenging after introducing oral targeted agents. This study aims at comparing patients’ and hematologists’ preferences for attributes of CLL treatments. An online cross-sectional survey has been delivered to clinicians and patients affected by CLL in Italy. A discrete choice experiment has been conducted so to estimate each attribute’s relative importance (RI) and assess the preference weight for each level of each attribute. An expert panel agreed on investigating the following attributes: progression-free survival (PFS) and measurable residual disease, route of administration/therapy duration and follow-up frequency, incidence of diarrhea (episodes/day), serious infections (grade 3 or 4), and atrial fibrillation. Overall, 746 patients and 109 clinicians accessed the survey, and 215 and 69, respectively, filled it in. The most important attributes were PFS (RI 30%) for hematologists and the risk of severe infections (RI 24%) for patients. Clinicians rated preference for maximum efficacy and lowest risk of severe infection very high (30%). Both patients and clinicians preferred oral administration while considering duration of therapy less relevant. The frequency of hospital appointments was negligible for patients, while clinicians preferred a quarterly frequency. Considering all attributes, diarrhea was weighted more by clinicians than by patients. Atrial fibrillation was not relevant for clinicians, while it was not negligible for patients. In conclusion, clinicians and patients favor an oral therapy, including continuous treatment, if associated with prolonged PFS, albeit with particular attention to the risk of serious infections. |
format | Online Article Text |
id | pubmed-9436277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-94362772022-09-07 What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment Laurenti, Luca Gaidano, Gianluca Mauro, Francesca Romana Molica, Stefano Pasqualetti, Patrizio Scarfò, Lydia Ghia, Paolo Hemasphere Article Several treatment options are available for chronic lymphocytic leukemia (CLL) and, for this reason, treatment choice can result challenging after introducing oral targeted agents. This study aims at comparing patients’ and hematologists’ preferences for attributes of CLL treatments. An online cross-sectional survey has been delivered to clinicians and patients affected by CLL in Italy. A discrete choice experiment has been conducted so to estimate each attribute’s relative importance (RI) and assess the preference weight for each level of each attribute. An expert panel agreed on investigating the following attributes: progression-free survival (PFS) and measurable residual disease, route of administration/therapy duration and follow-up frequency, incidence of diarrhea (episodes/day), serious infections (grade 3 or 4), and atrial fibrillation. Overall, 746 patients and 109 clinicians accessed the survey, and 215 and 69, respectively, filled it in. The most important attributes were PFS (RI 30%) for hematologists and the risk of severe infections (RI 24%) for patients. Clinicians rated preference for maximum efficacy and lowest risk of severe infection very high (30%). Both patients and clinicians preferred oral administration while considering duration of therapy less relevant. The frequency of hospital appointments was negligible for patients, while clinicians preferred a quarterly frequency. Considering all attributes, diarrhea was weighted more by clinicians than by patients. Atrial fibrillation was not relevant for clinicians, while it was not negligible for patients. In conclusion, clinicians and patients favor an oral therapy, including continuous treatment, if associated with prolonged PFS, albeit with particular attention to the risk of serious infections. Lippincott Williams & Wilkins 2022-08-31 /pmc/articles/PMC9436277/ /pubmed/36081648 http://dx.doi.org/10.1097/HS9.0000000000000771 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Laurenti, Luca Gaidano, Gianluca Mauro, Francesca Romana Molica, Stefano Pasqualetti, Patrizio Scarfò, Lydia Ghia, Paolo What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment |
title | What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment |
title_full | What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment |
title_fullStr | What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment |
title_full_unstemmed | What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment |
title_short | What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment |
title_sort | what are the attributes prioritized in the choice of therapy in chronic lymphocytic leukemia? a patient-physician cross-matching analysis of a discrete choice experiment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436277/ https://www.ncbi.nlm.nih.gov/pubmed/36081648 http://dx.doi.org/10.1097/HS9.0000000000000771 |
work_keys_str_mv | AT laurentiluca whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment AT gaidanogianluca whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment AT maurofrancescaromana whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment AT molicastefano whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment AT pasqualettipatrizio whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment AT scarfolydia whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment AT ghiapaolo whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment |